- Home
- LUNG vs LXEO Comparison
LUNG vs LXEO Comparison
Compare LUNG & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LUNG | LXEO |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 663.5M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LUNG | LXEO |
|---|---|---|
| Price | $2.36 | $9.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $6.81 | ★ $18.90 |
| AVG Volume (30 Days) | 827.0K | ★ 1.5M |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $91,664,000.00 | N/A |
| Revenue This Year | $9.21 | N/A |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.59 | N/A |
| 52 Week Low | $1.31 | $1.45 |
| 52 Week High | $9.37 | $10.99 |
Technical Indicators
Market Signals| Indicator | LUNG | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 46.64 |
| Support Level | $2.18 | $8.93 |
| Resistance Level | $2.34 | $10.99 |
| Average True Range (ATR) | 0.16 | 0.61 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 33.67 | 25.24 |
Price Performance
Historical ComparisonAbout LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.